Mild Cognitive Impairment Clinical Trial
— AETMCIOfficial title:
Mild Cognitive Impairment:Cerebrovascular Dysfunction and Exercise
Verified date | October 2016 |
Source | University of Texas Southwestern Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is being done to find out whether regulation of brain blood flow is altered in
patents with mild cognitive impairment (those who have memory problems but otherwise healthy)
when compared with healthy elderly individuals. In addition, this study will determine
whether exercise training improves brain blood flow, brain structure, and brain function in
patients with mild cognitive impairment (MCI).
This is a research study because at present the investigators know little about brain blood
flow regulation in patients with mild cognitive impairment. The investigators also know
little about whether exercise training improves brain blood flow, brain structure, and brain
function in patients with mild cognitive impairment.
Status | Completed |
Enrollment | 80 |
Est. completion date | September 2016 |
Est. primary completion date | September 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 55 Years to 80 Years |
Eligibility |
Inclusion Criteria: 1. Age 55-80 years old, Male or Female 2. Control Subjects: absence of cognitive complaints and normal performance in Uniform Data Set (UDS) neuropsychological tests. 3. For patients: Diagnosis of amnestic MCI (single and multiple domains) by Petersen's criteria (as modified for ADNI-GO study). 4. Stable medical condition for > 6 months 5. Sable medications for >2 months (use of cholinesterase inhibitors, or prior use of multivitamins is allowed) 6. Caregiver/informant available to accompany patient for scheduled visits in case the patient develops cognitive impairment that interferes with independent study participation. 7. Fluency of patient and caregiver in English 8. Ability to return to clinic for additional visits over a 12 month period. 9. = 10 years of education or enough work history to exclude mental retardation. 10. Adequate visual and auditory acuity to allow neuropsychological testing. 11. Screening laboratory tests and ECG without significant abnormalities that might interfere with the study. 12. Physical ability to undergo endurance exercise training. Exclusion Criteria: 1. Diagnosis of Alzheimer's Disease or other type of dementia. 2. Participant enrolled in any other investigational drug study within 2 months or longer, depending on the investigational drug half-life. 3. Modified Hachinski Score = 4. 4. Subject has history in the past 2 years of epileptic seizures, or DSM-IV criteria of any major psychiatric disorders. 5. Past history or MRI evidence of brain damage including significant trauma, stroke, hydrocephalus, mental retardation or serious neurological disorder. 6. Carotid stent or sever stenosis. 7. Significant history of active alcoholism or drug abuse. 8. History of myocardial infarction within the previous year. Unstable cardiac, renal, lung, liver or other severe chronic diseases. 9. Uncontrolled hypertension (Systolic Blood Pressure (SBP) =160, Diastolic Blood Pressure (DBP) =100)or hypotension (SBP <100 mmHg). 10. Currently diagnosed and being treated for Diabetes Mellitus (DM). 11. Obesity with Body Mass Index (BMI) = 35. 12. History of familial early onset (<55 years old) dementia 13. Pacemaker or other medical device of metal that precludes performing MRI. 14. Subjects who have been engaged in moderate intensity aerobic exercise training for > 30 minutes, 3 times per week over the past 2 years. 15. History of a clinical diagnosis of B12 deficiency or hypothyroidism. (stable treatment for at least 3 months is allowed). 16. Chronic inflammatory diseases including, lupus, rheumatoid arthritis and polymyalgia rheumatica. Prohibited Medications: - narcotics - anti-Parkinsonian medications - anti-convulsants for treatment of seizure disorder - drugs that can influence psychometric test results. - Subjects on a statins or non-steroidal anti-inflammatory drug (NSAID) are eligible but must be on a stable dose for at least 2 months. |
Country | Name | City | State |
---|---|---|---|
United States | UT Southwestern ADC/Institute for Exercise and Environmental Medicine | Dallas | Texas |
Lead Sponsor | Collaborator |
---|---|
University of Texas Southwestern Medical Center | National Institute on Aging (NIA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cognitive function | A comprehensive battery of neuropsychological tests focused on memory and executive function will be used to assess effects of exercise on cognitive function. | One year | |
Secondary | Cerebrovascular function | Transcranial Doppler and perfusion magnetic resonance imaging (MRI) will be used to measure cerebrovascular function/brain perfusion before and after exercise training. | One year | |
Secondary | Brain tissue volume and white matter integrity | Magnetic resonance imaging (MRI) will be used to measure changes in brain volume and white matter integrity before and after exercise training. | One year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04513106 -
Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial
|
N/A | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Active, not recruiting |
NCT03167840 -
Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment
|
N/A | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Not yet recruiting |
NCT05041790 -
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
|
Phase 4 | |
Recruiting |
NCT04121156 -
High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
Completed |
NCT02774083 -
Cognitive Training Using Feuerstein Instrumental Enrichment
|
N/A | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Enrolling by invitation |
NCT06023446 -
Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
|
||
Completed |
NCT04567745 -
Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers
|
Phase 1 | |
Recruiting |
NCT05579236 -
Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
|
||
Completed |
NCT03583879 -
Using Gait Robotics to Improve Symptoms of Parkinson's Disease
|
N/A | |
Terminated |
NCT02503501 -
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
|
Phase 2 | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Active, not recruiting |
NCT05204940 -
Longitudinal Observational Biomarker Study
|
||
Recruiting |
NCT02663531 -
Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease
|
N/A | |
Recruiting |
NCT06150352 -
Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
|
||
Recruiting |
NCT03507192 -
Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.
|
N/A |